Research Article
The Impact of COVID-19 on Hospitalised COPD Exacerbations in Malta
Table 1
Demographics and comorbidities of patients hospitalised with AECOPD and COPD pre-admission treatment.
| Patient demographics | 2019 | 2020 | Chi-square | value | | % | | % | | |
| Gender—male | 199 | 76.5% | 89 | 74.8% | 0.137 | 0.711 | Gender—female | 61 | 23.5% | 30 | 25.2% | Active smoker (within the last 6 months) | 102 | 54.0% | 38 | 43.7% | 2.524 | 0.112 | Comorbidity | Ischaemic heart disease | 80 | 30.8% | 28 | 23.5% | 2.028 | 0.154 | Chronic heart failure | 103 | 39.6% | 47 | 39.5% | 0.000 | 0.986 | Hypertension | 159 | 61.1% | 78 | 65.5% | 0.879 | 0.349 | Diabetes mellitus | 71 | 27.3% | 34 | 28.6% | 0.057 | 0.812 | Asthma | 17 | 6.5% | 5 | 4.2% | 0.811 | 0.368 | Cerebrovascular disease | 22 | 8.4% | 9 | 7.6% | 0.086 | 0.770 | Peripheral vascular disease | 19 | 7.3% | 5 | 4.2% | 1.361 | 0.243 | Pulmonary embolism/deep vein thrombosis | 11 | 4.2% | 3 | 2.5% | 0.688 | 0.407 | Active malignancy | 27 | 10.4% | 18 | 15.1% | 1.771 | 0.183 | Psychiatric history | 44 | 16.9% | 23 | 19.3% | 0.257 | 0.612 | COPD pre-admission treatment | SABA | 179 | 71.0% | 90 | 78.3% | 2.108 | 0.146 | LABA | 136 | 54.0% | 57 | 49.6% | 0.614 | 0.433 | SAMA | 158 | 62.7% | 77 | 67.0% | 0.622 | 0.430 | LAMA | 32 | 12.7% | 21 | 18.3% | 1.977 | 0.160 | ICS | 122 | 48.4% | 45 | 39.1% | 2.744 | 0.098 | Home nebulisers | 21 | 8.3% | 6 | 5.2% | 1.167 | 0.280 | Home NIV | 6 | 2.4% | 3 | 2.6% | 0.014 | 0.906 | Home LTOT | 64 | 25.4% | 29 | 25.0% | 0.007 | 0.935 |
|
|
SABA: short-acting beta-agonist; LABA: long-acting beta-agonist; SAMA: short-acting muscarinic antagonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroid use; NIV: non-invasive ventilation; LTOT: long-term oxygen therapy.
|